Raymond James analyst Steven Seedhouse downgraded Editas Medicine (EDIT) to Market Perform from Outperform. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on EDIT: Editas Medicine reports Q3 EPS (75c), consensus (75c) Is EDIT a Buy, Before Earnings? Editas Medicine price target lowered to $9 from $27 at Wells Fargo Editas Medicine price target lowered to $12 from $20 at Chardan Editas Medicine price target lowered to $10 from $18 at Baird